BOSTON--(BUSINESS WIRE)--Jul 28, 2026--
REEV announced today that it has initiated a pivotal clinical study of DREEVEN, the company's intelligent robotic knee-ankle-foot orthosis designed to restore mobility and independence for stroke survivors with chronic gait impairment. Stroke is among the leading causes of long-term disability in the United States. According to the American Stroke Association, more than 80% of stroke survivors experience gait impairment. Most experience some gait improvement during the first two months of recovery, but community ambulation remains compromised. Gait ability is an essential predictor of functional independence, quality of life, and long-term survival after stroke.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260723594218/en/
The study will evaluate how DREEVEN supports patient mobility and performance during functional activities, including walking on both flat and uneven surfaces, navigating stairs, and completing sit-to-stand transfers. In addition to in-clinic sessions, the study incorporates home monitoring, enabling evaluation of DREEVEN's performance and safety during real-world daily activities. Data will be collected as participants move through their lives, not just in the clinic.
Lou Awad, PT, DPT, PhD, director of Boston University's Neuromotor Recovery Laboratory, is the study's Principal Investigator. Encompass Health of Braintree, MA, and Whittier Rehabilitation Hospital of Bradford, MA, are participating as clinical sites. These partners bring deep expertise in stroke rehabilitation and a shared understanding of meaningful recovery. This study marks a critical milestone in REEV's journey toward FDA clearance and commercial launch.
"The clinicians in these facilities work with stroke survivors every day – they understand the gap between what patients can do today and what they need to do to live independently,” said Amaury Ciurana, CEO of REEV. “These partners are helping us generate clinical evidence while also building the pathway to real-world patient access once DREEVEN receives FDA clearance."
Dr. Brigid Dwyer, MD notes, "One of the most valuable aspects of this study is its incorporation of home monitoring alongside in-clinic sessions. Evaluating device performance in real-world settings gives us a more complete picture of how DREEVEN may support patients in their daily lives."
This study builds on REEV's established clinical foundation. SENSE, the company's FDA-registered, HIPAA-compliant gait analysis system, is already in use at rehabilitation centers across the country. It gives clinicians objective, real-time insight into each patient's unique gait pattern. SENSE data is designed to customize DREEVEN’s motor control – calibrating the precise level of assistance each patient needs during their daily activities.
REEV is expanding access to effective mobility solutions for stroke survivors living with chronic gait impairments through this pivotal study and the Neuro-Integration Program. This clinical collaboration with leading stroke centers ensures that when DREEVEN is cleared, the infrastructure to support patients will already be in place.
Rehabilitation centers interested in learning about DREEVEN's pivotal study or REEV's Neuro-Integration Program are encouraged to contact megan.hoogmoed@reev.care.
DREEVEN is an investigational device that has not been cleared for commercial sale in the United States.
About REEV
REEV is a medical technology company with offices in Toulouse, France, and Boston, Massachusetts. Its mission is to reinvent mobility care for millions of people facing physical limitations due to neurological conditions, aging, or orthopedic disorders through intelligent, lightweight wearable robotics. REEV’s technology portfolio includes REEV SENSE, a precise gait analysis system, and DREEVEN, a prescription-based, intelligent robotic knee-ankle-foot orthosis, currently in clinical trials. Connect with REEV on LinkedIn.
The first smart, patient-centric, motorized orthosis for everyday life after stroke.
BUFFALO, N.Y. (AP) — The man on trial in the stabbing of Salman Rushdie chose Tuesday not to testify or call any witnesses in the federal terrorism case, which is expected to head to the jury as soon as Wednesday.
Hadi Matar's lawyer told the court that the 28-year-old — who already has been convicted of state-level attempted murder charges — wouldn't take the stand at his trial on charges that include engaging in an act of transnational terrorism.
“At this time, the defense rests,” attorney Nathaniel Barone said. Matar has pleaded not guilty.
Prosecutors also rested their case Tuesday, and closing arguments are expected Wednesday morning. Rushdie, the prize-winning author of novels including “Midnight’s Children” and the controversial “The Satanic Verses,” testified last week about the 2022 attack that nearly killed him and left him blind in one eye.
Rushdie was about to give a talk — about writers' safety, no less — when his attacker climbed on stage behind him and stabbed him 15 times in front of a stunned audience at the Chautauqua Institution, an arts and intellectual retreat.
Spectators and another speaker, Henry Reese, scrambled to aid Rushdie and restrain the assailant, who was arrested by law enforcement officers assigned to the event. He initially gave authorities a fake driver's license, but Matar soon disclosed his real name to a state trooper, according the trooper's testimony and body camera video.
Prosecutors contend that Matar was acting upon a former Iranian leader's 1989 call for Rushdie's death because of “The Satanic Verses,” which ignited protests across the Muslim world. Some believers considered it blasphemous because of a dream sequence featuring Islam's Prophet Muhammad.
Rushdie, who was born in India into a Muslim family and is now a U.S. citizen, went into hiding for years. He gradually emerged after Iran's government distanced itself in 1998 from the late Supreme Leader Ayatollah Ruhollah Khomeini 's fatwa, or religious order, about the writer. Khomenei died in 1989.
Prosecutors say Matar, a U.S.-born American-Lebanese citizen, acted out of loyalty to Iran and to the Lebanon-based Hezbollah militant group. The late Hezbollah leader Hassan Nasrallah said in 2006 that if someone had carried out the fatwa, European newspapers wouldn't have dared publish a caricature of Muhammad that was causing an uproar in Muslim communities.
Iran’s government denied involvement in the 2022 stabbing, though its Foreign Ministry’s then-spokesperson suggested Rushdie courted trouble by insulting Islam. Nasrallah did not comment on the attack.
The U.S. government designates Hezbollah as a foreign terrorist organization. Matar, too, described the group in a 2016 paper as a terrorist organization, Assistant U.S. Attorney Timothy Lynch said Tuesday during legal arguments when jurors were out of the room.
Matar started researching Rushdie's whereabouts in 2020, eventually writing in private notes that “we need to kill him ASAP” and “become a warrior and just get it over with,” prosecutors have said.
Matar didn't testify at his 2025 state court trial, either. His lawyer has said federal prosecutors are making implications but don't have proof about the man’s intentions.
“There’s no facts. There’s no hard evidence,” Barone said in an interview outside the courthouse last week. “There could be a number of reasonable, plausible explanations as to what he was thinking.”
Barone unsuccessfully argued Tuesday that prosecutors hadn't presented enough evidence for the trial to continue. A judge declined Barone's request to dismiss the case.
Matar is currently serving a 25-year state prison sentence. If convicted in the federal case, he faces a potential life sentence.
Peltz reported from New York.
In this courtroom sketch, Salman Rushdie, left, testifies in federal court during the terrorism trial for Hadi Matar, Rushdie's alleged attacker, shown second from bottom left, Thursday, July 23, 2026, in Buffalo, N.Y. (Alexandra Newbould via AP)
In this courtroom sketch, Salman Rushdie, left, testifies in federal court during the terrorism trial for Hadi Matar, Rushdie's alleged attacker, Thursday, July 23, 2026, in Buffalo, N.Y. (Alexandra Newbould via AP)
FILE - Hadi Matar walks in to the Chautauqua County court in Mayville, N.Y., May, 16, 2025. (AP Photo/Adrian Kraus, File)
FILE - Novelist Salman Rushdie attends the premiere of the documentary film "Knife: The Attempted Murder of Salman Rushdie" during the Sundance Film Festival on Jan. 25, 2026, at The Ray in Park City, Utah. (AP Photo/Chris Pizzello, File)
In this courtroom sketch, Hadi Matar, center, sits in federal court during his terrorism trial for his alleged attack on Salman Rushdie, Wednesday, July 22, 2026, in Buffalo, N.Y. (Alexandra Newbould via AP)
